← Leaderboards
Vikas R. Dharnidharka
University Of Florida
$8,201,291
Attributed
$8,817,592
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,485,397 · 13
By mechanism
R01$5,400,397 · 3
U01$2,879,102 · 1
P50$1,667,805 · 1
R21$251,206 · 1
R34$235,500 · 1
M01$51,387 · 6
Top collaborators
- David Adam Axelrod2 shared
- Sanjay Jain2 shared
Most similar at University Of Florida
Same institution · by research overlap
- Yi Guo$3,756,653
- Hui Shao$4,879,138
- Caitrin W McDonough$1,019,914
- Desmond Arthur Schatz$16,657,017
- Tezcan Ozrazgat Baslanti$579,876
Others in their field
Top investigators on “Transplant Recipients”
- Leland H Hartwell · Fred Hutchinson Cancer Research Center$84,240,435
- Peter Scott Heeger · Case Western Reserve University$83,635,934
- Joren C Madsen · Massachusetts General Hospital$58,876,734
- Mary M Horowitz · Medical College Of Wisconsin$55,693,586
- Peter G Stock · University Of California San Francisco$39,243,787
- Leslie S Kean · Emory University$39,217,487
Research focus
Transplant RecipientsResourcesMorbidity - Disease RateTransplantationOrgan TransplantationProgramsHigh RiskProspectiveCharacteristicsCessation Of LifeSamplingPharmaceutical PreparationsImmunosuppressionAllograftingRegistriesBaseDatabasesPreventCohortEventChildInfectionProtocols DocumentationAcute
Grant awards (26)
Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH)$945,993
U01 · FY2025 · CA · contact PI
Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity 2 (CISTEM2)$561,098
R01 · FY2025 · DK · contact PI
An adaptive, randomized controlled trial to treat BK polyomavirus infections (BKPyV) in pediatric kidney transplant recipients$235,500
R34 · FY2025 · AI · contact PI
Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH)$763,520
U01 · FY2024 · CA · contact PI
Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity2 (CISTEM2)$671,504
R01 · FY2024 · DK · contact PI
Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH)$182,404
U01 · FY2024 · CA · contact PI
Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH)$987,185
U01 · FY2023 · CA · contact PI
Pediatric Kidney Single Cell Atlas Project$796,163
P50 · FY2023 · DK
Pediatric Kidney Single Cell Atlas Project$871,642
P50 · FY2022 · DK
Metagenomic shotgun microbial sequencing in post-transplant lymphoproliferative disorders (PTLD-MSMS)$567,741
R01 · FY2022 · AI · contact PI
Metagenomic shotgun microbial sequencing in post-transplant lymphoproliferative disorders (PTLD-MSMS)$641,440
R01 · FY2021 · AI · contact PI
Metagenomic shotgun microbial sequencing in post-transplant lymphoproliferative disorders (PTLD-MSMS)$522,763
R01 · FY2020 · AI · contact PI
Metagenomic shotgun microbial sequencing in post-transplant lymphoproliferative disorders (PTLD-MSMS)$579,282
R01 · FY2019 · AI · contact PI
Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity$363,763
R01 · FY2018 · DK · contact PI
Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity$364,644
R01 · FY2017 · DK · contact PI
Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity$368,018
R01 · FY2016 · DK · contact PI
Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity$332,065
R01 · FY2015 · DK · contact PI
Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity$428,079
R01 · FY2014 · DK · contact PI
CHRONIC KIDNEY DISEASE IN CHILDREN STUDY$3,235
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: TRIAL OF TACROLIMUS WITH STEROIDS AND DACLIZUMAB VS STEROID FRE$809
M01 · FY2009 · RR · contact PI
TRIAL OF TACROLIMUS WITH STEROIDS AND DACLIZUMAB VS STEROID FREE TACROLIMUS$24,120
M01 · FY2007 · RR · contact PI
CHRONIC KIDNEY DISEASE IN CHILDREN STUDY$8,040
M01 · FY2007 · RR · contact PI
Pediatric Transplant Infections and Outcomes$142,081
R21 · FY2006 · DK · contact PI
TRIAL OF TACROLIMUS WITH STEROIDS AND DACLIZUMAB VS STEROID FREE TACROLIMUS$12,543
M01 · FY2006 · RR · contact PI
CHRONIC KIDNEY DISEASE IN CHILDREN STUDY$2,640
M01 · FY2006 · RR · contact PI
Pediatric Transplant Infections and Outcomes$109,125
R21 · FY2005 · DK